araag2/HINT huggingface dataset:
Clinical trial NCT00098514 (phase 1, status: completed)
Conditions: unspecified adult solid tumor, protocol specific
ICD codes: H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: talotrexin ammonium
SMILES: NC1=NC(N)=C2N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCCNC(=O)C3=CC=CC=C3C(O)=O)C(O)=O)C=NC2=N1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of malignant solid tumor

               -  Metastatic or inoperable disease

          -  No known curative or survival-prolonging palliative therapy exists OR failed these
             prior therapies

          -  No leukemia

          -  No primary CNS tumor

          -  No third-space fluid collection (i.e., pleural effusion, ascites)

               -  Clinically insignificant small pleural or peritoneal effusions identified by CT
                  scan, MRI, or other diagnostic test allowed

          -  No active* brain metastases, including the following:

               -  Evidence of cerebral edema by CT scan or MRI

               -  Progression since prior imaging study

               -  Requirement for steroids

               -  Clinical symptoms of/from brain metastases NOTE: *Treated and/or stable brain
                  metastasis allowed provided patient is asymptomatic

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 2 months

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  RBC folate ≥ lower limit of normal

        Hepatic

          -  Bilirubin normal

          -  SGOT and SGPT ≤ 2.5 times upper limit of normal

        Renal

          -  Creatinine clearance ≥ 50 mL/min

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other uncontrolled serious medical or psychiatric illness

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior bone marrow transplantation

        Chemotherapy

          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

        Endocrine therapy

          -  See Disease Characteristics

        Radiotherapy

          -  More than 3 weeks since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  At least 3 weeks since prior surgery

        Other

          -  Recovered from prior therapy

          -  More than 3 weeks since prior antifolate therapy
Clinical trial NCT00147875 (phase 1/phase 2, status: completed)
Conditions: hodgkin's disease
ICD codes: C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, C81.70
Drugs: prednisone, vinblastine, doxorubicin (adriamycin), gemcitabine
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Hodgkin's lymphoma (histologically proven)

          -  Clinical stage IIB (with risk factors bulky mediastinal mass and/or extranodal
             involvement), III, or IV

          -  No prior antitumor therapy

          -  Age 60 to 75 years

          -  WHO performance status 0-2

          -  Normal pulmonary function

          -  Written informed consent

        Exclusion Criteria:

          -  The following histologies are excluded: lymphocyte predominant HD

          -  Leukocytes < 2,500/microL

          -  Platelets < 100,000/microL
Clinical trial NCT01046630 (phase 1, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: azd6765, ketamine, placebo
SMILES: N[C@@H](CC1=CC=CC=N1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented clinical diagnosis meeting criteria from the DSM-IV by structured clinical
             interview,major depressive disorder, single episode or recurrent

          -  Outpatient status at screening and at randomisation

        Exclusion Criteria:

          -  A major depression disorder which has a major impact on the subjects current
             psychiatric status

          -  Subjects not allowed to use mood stabilizers, antidepressants or other antipsychotic
             or psychoactive drugs

          -  Subjects with lifetime history of schizophrenia, bi-polar, psychosis and psychotic
             depression
Clinical trial NCT01405963 (phase 1, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: amg 157 matching placebo, amg 157
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects with history of mild atopic asthma between 18 and 60
             years-of-age

          -  Body mass index (BMI) between 18 and 35 kg/m2

          -  Normal or clinically acceptable physical examination (PE), clinical laboratory values,
             and ECG; clinically acceptable PE includes history of mild atopic asthma

          -  Used only inhaled short-acting β2-agonists infrequently to treat asthma

          -  No current exposure to allergens to which subject experiences asthmatic responses

          -  No other lung disease, exacerbations of asthma or lower respiratory tract infections
             for at least 6 weeks prior to screening

          -  Positive skin prick test to common aeroallergens at screening

          -  Additional inclusion criteria apply

        Exclusion Criteria:

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluation, procedures or completion;

          -  History or current medical conditions that are contraindicated for methacholine
             challenge, such as myocardial infarction or stroke within previous 3 months, known
             cardiac disease, uncontrolled hypertension and aortic or cerebral aneurysm

          -  Evidence of active or suspected bacterial, viral, fungal or parasitic infections
             within past 6 weeks

          -  Subject has know type I/II diabetes

          -  History of residential exposure to tuberculosis or has a positive PPD or QuantiFERON
             test within 4 weeks before randomization

          -  Subject who has history of malignancy of any type within 5 years prior to enrollment

          -  Subjects tested positive for drugs/alcohol or nicotine use at screening

          -  Subjects tested positive for HIV, Hep B or Hep C

          -  Additional exclusion criteria apply
Clinical trial NCT00529100 (phase 1/phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed phase 1, cisplatin phase 1, pemetrexed phase 2, cisplatin phase 2
SMILES: [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

        Some of the requirements to be in this study are:

          -  Patient must be at least 18 years old.

          -  Patient must have been diagnosed with non-small cell lung cancer.

          -  Patient must be able to visit the doctor's office once a week.

          -  Patient must have adequate blood, liver, lungs and kidney function within the
             requirements of this study.

          -  Female patients of child-bearing potential must test negative for pregnancy at the
             time of enrollment based on a serum pregnancy test. Male and female patients must
             agree to use a reliable method of birth control during and for 3 months following the
             last dose of study drug.

        Exclusion Criteria:

        Patients cannot participate in this study for any of the following reasons:

          -  Patient has previously had chemotherapy.

          -  Patient has previously had thoracic radiation therapy.

          -  Patient has received treatment within the last 30 days with a drug that has not
             received approval by Health Canada for any indication at the time of study entry.

          -  Female patient is pregnant or breast-feeding.

          -  Patient is unsuitable to participate in the study in the opinion of the investigator.

          -  Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, or
             dexamethasone.
Clinical trial NCT01385657 (phase 1, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: placebo, dupilumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCO
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, 18 years or older;

          2. Chronic AD diagnosed by the Eichenfield revised criteria of Hannifin and Rajka that
             had been present for at least 3 years before the screening visit;

          3. Eczema Area and Severity Index (EASI) score ≥ 12 at the screening and baseline visits;

          4. Investigator's Global Assessment (IGA) score ≥ 3 at the screening and baseline visits;

          5. ≥ 10% body surface area (BSA) of AD involvement at the screening and baseline visits;

          6. History of inadequate response to a stable (≥ 1 month) regimen of topical
             corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before
             the screening visit.

        Exclusion Criteria:

          1. Positive Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the
             screening visit;

          2. Treatment with an investigational drug within 8 weeks or within 5 half-lives, if
             known, whichever is longer, before the baseline visit;

          3. Treatment with leukotriene inhibitors within 4 weeks before the baseline visit;

          4. Treatment with systemic corticosteroids within 4 weeks before the baseline visit;

          5. Treatment with topical corticosteroids, tacrolimus, and/or pimecrolimus within 1 week
             before the baseline visit;

          6. Systemic treatment for AD with an immunosuppressive/immunomodulating substance within
             4 weeks before the baseline visit;

          7. Chronic or acute infection requiring treatment with oral or IV antibiotics,
             antivirals, or antifungals within 4 weeks before the screening visit or superficial
             skin infections within 1 week before the screening visit;

          8. Known history of human immunodeficiency virus (HIV) infection;

          9. History of clinical parasite infection, other than treated trichomoniasis;

         10. History of malignancy within 5 years before the baseline visit, with the following
             exceptions: participants with a history of completely treated carcinoma in-situ of
             cervix, and non-metastatic squamous or basal cell carcinoma of the skin were allowed;

         11. Any medical or psychiatric condition which, in the opinion of the investigator or the
             sponsor's medical monitor, would place the participant at risk, interfere with
             participation in the study, or interfere with the interpretation of study results;

         12. Pregnant or breast-feeding women;

         13. Unwilling to use adequate birth control, if of reproductive potential and sexually
             active.
Clinical trial NCT01702740 (phase 1, status: completed)
Conditions: lupus erythematosus, cutaneous, lupus erythematosus, systemic
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: 1 mg/kg cnto 136, 4 mg/kg cnto 136, 10 mg/kg cnto 136, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of cutaneous lupus erythematosus (CLE, including subacute cutaneous lupus
             erythematosus, discoid lupus erythematosus, or lupus erythematosus tumidus) or
             systemic lupus erythematosus (SLE)

               -  Had a body weight less than or equal to 100 kg

               -  Patients in Part A who were taking systemic medications for CLE had to be on a
                  stable dose for 4 weeks before the first study agent infusion

               -  Patients in Part B taking systemic medications for SLE had to be on a stable dose
                  for at least 3 months before the first study agent infusion

               -  Given informed consent and willing and able to adhere to the study visit schedule
                  and other protocol requirements; agreed to avoid alcohol intake; and took
                  adequate measures to prevent pregnancy

        Exclusion Criteria:

          -  Significant history of or concurrent medical condition (other than lupus)

          -  Use of specific previous or concurrent medications or investigational therapies

          -  Known or suspected allergy to the study agent or it constituents, having recently
             donated blood, or having any significant laboratory test values requiring intervention

          -  Patients with SLE in Part B could not have active central nervous system lupus
Clinical trial NCT00170053 (phase 1, status: completed)
Conditions: kidney diseases
ICD codes: I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: sirolimus
SMILES: CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          1. Primary deceased or living donor renal transplant recipients

          2. Re-transplant recipients for which the first kidney transplant was lost for technical
             reasons with no sensitization (panel-reactive antibody [PRA] < 20%) or 1st lost due to
             recurrent disease, that is not steroid responsive.

          3. Age > 18

          4. Negative pregnancy test if female and of childbearing age. In addition, females of
             childbearing age must agree to use effective contraception for the duration of the
             study.

          5. Patient must sign informed consent prior to transplant.
Clinical trial NCT00985907 (phase 1/phase 2, status: terminated)
Conditions: multiple myeloma, patient participation
ICD codes: C90.01, C90.02, C90.00
Drugs: doxil, melphalan, bortezomib
SMILES: N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

        Disease Characteristics:

          1. Patient previously diagnosed with multiple myeloma; Durie-Salmon Stage I, II, or III
             based on standard criteria

          2. Progressive disease. For non-secretory multiple myeloma, progressive disease is
             defined as bone marrow biopsy with > 25% increase in plasma cells or an absolute
             increase of at least 10% over prior known level. Alternatively, development of new or
             worsening of existing lytic bone lesions or soft tissue plasmacytomas, or
             hypercalcemia (serum calcium >11.5 mg/dL), or relapse from complete response.

        Patient Characteristics:

          1. 18 yrs or older

          2. Patient has given voluntary written informed consent.

          3. Unless post-menopausal or surgically sterilized, a female must be willing to use an
             acceptable method of birth control

          4. Male patient must agree to use an acceptable method for contraception for the duration
             of the study.

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

          6. Life expectancy is at least 3 months.

          7. • Absolute Neutrophil Count (ANC) over 1,000/ul without the use of colony stimulating
             factors

               -  Platelets over 50,000/ul without transfusion support 7 days

               -  Bilirubin 2.0 mg/dl or less

               -  aspartate aminotransferase (AST) 4 times or less upper limit normal Prior Therapy
                  for Multiple Myeloma: Patients must have had at least 2 prior therapeutic
                  regimens

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  History of allergic reaction to compounds containing boron or mannitol.

          -  Active uncontrolled viral (including HIV), bacterial, or fungal infection.

          -  Grade III or IV toxicity due to previous anti-neoplastic therapy

          -  More than Grade 2 motor or sensory neuropathy

          -  Myocardial infarction within 6 months of enrollment or New York Heart Association
             (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled
             arrhythmias, or electrocardiographic evidence of acute ischemia.

          -  For any patients whose lifetime cumulative doxorubicin dose exceeds 400mg/m2, patients
             with left ventricular ejection fraction (LVEF) less than 35% by multigated acquisition
             (MUGA) .

          -  Concurrent administration of liposomal doxorubicin, melphalan, and bortezomib (single
             or two drug combinations of these are permissible)

          -  Less than 3 weeks since most recent chemotherapy or concurrent chemotherapy

          -  Use of corticosteroids (mroe than 10 mg prednisone/day or equivalent)
Clinical trial NCT00255333 (phase 1, status: terminated)
Conditions: tumors
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: inno-105
SMILES: CSCC[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O
Reason stopped: 
    development of this compound was discontinued.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Have a histologically or cytologically confirmed diagnosis of a solid malignancy
             (patients may have either measurable or nonmeasurable disease).

          2. Be ≥18 years old.

          3. Not eligible for effective therapy likely to provide clinical benefit.

          4. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.

          5. Acceptable pretreatment clinical laboratory results.

          6. Life expectancy of greater than 12 weeks.

        Exclusion Criteria:

          1. Have received previous treatment with INNO-105.

          2. Have an active, uncontrolled systemic infection considered opportunistic, life
             threatening, or clinically significant at the time of treatment.

          3. Are pregnant or lactating.

          4. Have a psychiatric disorder(s) that would interfere with consent, study participation,
             or follow-up.

          5. Have received any chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major
             surgery, or irradiation, whether conventional or investigational, within 2 weeks of
             treatment in this study.

          6. Have not recovered from acute toxicity of all previous therapy prior to enrollment.

          7. Have symptomatic or untreated central nervous system (CNS) metastases.

          8. Have a susceptibility to hypotension, bradycardia, and/or hypopnea, such as patients
             with known coronary heart disease, arrhythmias, cerebral vascular disease, and chronic
             obstructive airways disease (CO2-retaining).
Clinical trial NCT00073723 (phase 1/phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: abi-007
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Patients must be:

          -  Histologically or cytologically confirmed advanced stage IV NSCLC with evidence of
             inoperable local recurrence or metastasis

          -  If female, non-pregnant and not lactating, with a negative serum pregnancy test, and
             either not of child-bearing potential or practicing an approved contraception method

          -  Eighteen years of age or older

          -  No other current active malignancy

          -  Measurable disease (defined by RECIST criteria) documented radiographically

          -  Patient must have received no prior chemotherapies for the treatment of metastatic
             disease. Radiation therapy to a major bone marrow-containing area must have been
             completed 3 or more weeks prior to study entry. Prior treatment with EGF-targeted
             therapies is permitted.

          -  If, at baseline, patient has ANC greater than or equal to 1.5 x 109 cells/L; platelets
             greater than or equal to 100 x 109 cells/L and Hgb greater than or equal to 9 g/dL

          -  If, at baseline, patient has AST and ALT of less than or equal to 2.5 x the upper
             limit of normal range; a total bilirubin NORMAL; creatinine levels less than or equal
             to 1.5 mg/dL and alkaline phosphatase levels less than or equal to 2.5 x the upper
             limit of normal range (unless alkaline phosphatase elevation is felt to be related to
             bone metastases and there is no radiologic evidence of hepatic metastasis)

          -  Expected survival of greater than 12 weeks

          -  ECOG performance status 0-1 (Karnofsky > 70)

          -  Patient or his/her legally authorized representative or guardian has been informed
             about the nature of the study, and has agreed to participate in the study, and signed
             the Informed Consent form prior to participation in any study-related activities.